TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2018

Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.

Noah Kornblum et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.